Angiotensin Peptides Potentiate SARS-CoV-2 Spike Protein–Receptor Interactions: Evidence and Implications

Study Background and Research Question

The renin-angiotensin system (RAS) is central to cardiovascular and renal regulation, with angiotensin peptides playing key roles in vascular tone modulation and blood pressure control. During the COVID-19 pandemic, focus intensified on the interface between RAS components and SARS-CoV-2, the virus responsible for COVID-19, due to its use of the angiotensin-converting enzyme 2 (ACE2) as the canonical cellular entry receptor. However, alternative receptors such as AXL and neuropilin-1 (NRP1) have also been implicated in viral entry, particularly in tissues with low ACE2 expression. The reference study by Oliveira et al. (Int. J. Mol. Sci. 2025, 26, 6067) addresses a critical question: Do naturally occurring angiotensin peptides modulate the interaction between the SARS-CoV-2 spike protein and its host cell receptors, and if so, what are the mechanistic and biological implications?

Key Innovation from the Reference Study

The central innovation of the study is the demonstration that angiotensin-derived peptides—including Angiotensin 1/2 (1-6) (Asp-Arg-Val-Tyr-Ile-His)—can directly enhance binding between the SARS-CoV-2 spike protein and the AXL receptor. This effect is both peptide-length and sequence dependent, with specific C-terminal and N-terminal truncations increasing this binding potency. The study moves beyond the conventional focus on ACE2 and explores a broader landscape of peptide-mediated modulation of viral entry pathways, thus bridging cardiovascular regulation and viral pathogenesis.

Methods and Experimental Design Insights

Oliveira et al. employed antibody-based binding assays to quantitatively assess the impact of various angiotensin fragments on the interaction between the SARS-CoV-2 spike protein and its primary (ACE2) and alternative (AXL, NRP1) receptors. The researchers systematically tested a panel of angiotensin peptides, including the canonical Angiotensin II (1–8), its C-terminal and N-terminal truncations (such as Angiotensin 1/2 (1–6), Angiotensin (1–7), Angiotensin III (2–8), and Angiotensin IV (3–8)), and modified analogs (e.g., Tyr4 phosphorylation or substitution). The binding responses were quantified to determine both specificity and relative enhancement across peptide variants.

Notably, the study design allowed for direct comparison between different peptide lengths and sequence modifications, enabling the identification of structural features responsible for the observed biological effects. The use of established binding assays ensures the reliability and reproducibility of the findings in the context of both cardiovascular regulation studies and emerging models of viral entry.

Core Findings and Why They Matter

The primary finding is that several angiotensin peptides, especially those with specific C-terminal or N-terminal modifications, significantly enhance the binding of SARS-CoV-2 spike protein to AXL. Angiotensin II (1–8) induced a two-fold increase in spike–AXL binding, while Angiotensin 1/2 (1–6) and Angiotensin (1–7) exhibited similar effects. N-terminally truncated peptides such as Angiotensin III (2–8) and Angiotensin IV (3–8) produced even greater enhancement, with Angiotensin IV eliciting a 2.7-fold increase. In contrast, the full-length Angiotensin I (1–10) did not affect spike–AXL binding, demonstrating the importance of peptide length and terminal sequence.

Modification of the tyrosine residue at position 4—either by substitution with valine or phosphorylation—further increased spike–AXL binding, highlighting a critical structural determinant within the Asp-Arg-Val-Tyr-Ile-His sequence. These findings indicate that specific features of angiotensin fragments, such as those embodied by Angiotensin 1/2 (1-6), can modulate viral receptor interactions independently of their classical roles in cardiovascular biology.

Importantly, while the strongest effect was observed for spike–AXL binding, Angiotensin IV was also able to enhance spike protein association with ACE2 and NRP1, albeit to a lesser extent. This suggests a broader regulatory potential of angiotensin peptides in the context of SARS-CoV-2 infection, with potential implications for tissue tropism and disease severity.

Comparison with Existing Internal Articles

The internal articles (e.g., Angiotensin 1/2 (1-6): Precision Tools for Cardiovascular Research) consistently highlight the value of Angiotensin 1/2 (1-6) in dissecting vascular tone modulation and renin-angiotensin system research. These resources emphasize the peptide’s high solubility, purity, and specificity for cardiovascular and renal assays. The findings by Oliveira et al. provide a new mechanistic layer, demonstrating that Angiotensin 1/2 (1-6) is not only a tool for cardiovascular regulation studies but also a relevant molecule for exploring viral receptor interactions. This alignment bridges established applications—such as blood pressure and vascular physiology—with emerging research domains involving infectious disease mechanisms (see mechanistic exploration and workflow guidance).

While the internal literature focuses on translational and mechanistic studies within the RAS, the reference paper uniquely elucidates the direct effect of angiotensin fragments on SARS-CoV-2 spike–receptor binding, thus expanding the experimental and conceptual utility of Asp-Arg-Val-Tyr-Ile-His hexapeptide fragments.

Limitations and Transferability

Several limitations must be considered. The primary assays employed in the study measure binding affinity in vitro, which, while informative, may not fully recapitulate the complexity of in vivo viral entry and pathogenesis. The enhancement of spike–AXL binding by angiotensin peptides does not directly equate to increased infectivity or clinical severity without further functional validation. Tissue-specific distribution, peptide concentrations, and proteolytic processing in physiological environments could significantly modulate these interactions. Additionally, the study does not address downstream signaling or cellular outcomes following enhanced spike–receptor binding.

Despite these caveats, the work provides a robust foundation for further investigations into the intersection of RAS biology and viral infection mechanisms, and it highlights the need for translational studies in relevant cell and animal models.

Protocol Parameters

• Peptide concentration range: The reference study used concentrations in the low micromolar range to assess binding enhancement; titration is recommended to establish effective windows for spike–receptor assays.
• Binding assay format: Antibody-based (ELISA-type) binding assays were employed to quantify spike–receptor interactions; ensure peptide solubility and stability under assay conditions.
• Sequence specificity: Both C-terminal and N-terminal truncations of angiotensin peptides should be included when profiling binding activities; modifications at tyrosine position 4 (substitution or phosphorylation) may be considered to probe structural requirements.
• Workflow compatibility: For cardiovascular regulation or renin-angiotensin system research, use validated peptide standards (such as Angiotensin 1/2 (1-6)) with high solubility in aqueous buffers for reproducibility.
• Peptide storage: Store lyophilized peptide and working solutions at -20°C to maintain stability over extended experimental timelines.

Why this cross-domain matters, maturity, and limitations

The evidence from Oliveira et al. demonstrates a concrete molecular bridge between cardiovascular peptide biology and viral entry mechanisms. By showing that angiotensin fragments can modulate SARS-CoV-2 spike–receptor binding, the study prompts researchers to reconsider the systemic effects of RAS modulation in the context of infectious disease. This cross-domain insight is particularly relevant for patients with underlying cardiovascular or renal conditions, who may have altered angiotensin peptide profiles and, potentially, differential susceptibility to SARS-CoV-2 infection. However, the translational maturity of these findings is limited by their in vitro scope; in vivo validation and mechanistic dissection in disease models are necessary next steps.

Research Support Resources

For researchers designing studies at the interface of vascular biology, renin-angiotensin system research, and viral pathogenesis, high-purity peptide reagents are essential. Angiotensin 1/2 (1-6) (SKU A1048), with the sequence Asp-Arg-Val-Tyr-Ile-His, is available from APExBIO and offers robust solubility and stability for binding and signaling assays. Its validated use in cardiovascular regulation studies, as well as its emerging role in viral receptor interaction research, supports reproducible and high-sensitivity workflows as outlined in both the reference study and internal resources.